Sutain

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sutain

Sutain is a prescription medicinal product containing the active ingredient Tiaprofenic acid, which is scientifically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its primary function is to provide general relief from pain and reduce the body's inflammatory response.

Property Description
Active ingredient Tiaprofenic acid
Form Tablet (oral, standard and sustained-release)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief from pain and inflammation
Origin Synthetic chemical compound

What Type of Medicine is Sutain?

Sutain is formally classified as an NSAID, specifically a propionic acid derivative. It is often prescribed where medical oversight is required, contrasting with common over-the-counter options. It is characterized as an analgesic and anti-inflammatory agent. Its oral administration in the form of a tablet allows for systemic action throughout the body, providing general relief.


Composition and Chemical Origin

The core component is the single-ingredient compound Tiaprofenic acid, which is a derivative of propionic acid. It is a synthetic drug, designed to specifically interact with the body's inflammatory pathways. Tiaprofenic acid is supplied as a racemic mixture of two enantiomers, a chemical feature shared by several other profen medications. Tiaprofenic acid acts by inhibiting prostaglandin synthesis. This means the drug blocks the body's key chemical messengers that cause pain and swelling.


General Purpose and Function

The general purpose of Sutain is to alleviate widespread pain and decrease associated swelling. It achieves this by briefly interfering with the production of certain chemical messengers, primarily prostaglandins, which signal and amplify discomfort. This action allows the medicine to provide effective symptomatic relief, such as easing the stiffness and discomfort associated with chronic inflammatory conditions. Its availability in sustained-release dosage forms further differentiates its use, designed to provide consistent anti-inflammatory action over an extended period.

Regulatory References

  1. NIH PubMed Central

What side effects are possible with Sutain?

Possible Side Effects and Safety Information

Sutain, which contains the Nonsteroidal Anti-inflammatory Drug (NSAID) Tiaprofenic acid, is associated with a range of officially documented adverse reactions classified by body system. The most common effects are primarily localized to the Gastrointestinal System, including dyspepsia, nausea, abdominal pain, and diarrhea. Other commonly reported reactions affect the Nervous System, such as headache, dizziness, and drowsiness.

As a class, NSAIDs carry serious, less common systemic risks highlighted in regulatory documentation. These include the risk of serious arterial thrombotic events, such as myocardial infarction (heart attack) and stroke. A further critical risk is the potential for severe gastrointestinal bleeding, ulceration, and perforation, which can occur without warning.

Category of Safety Consideration Regulatory Status
Urinary System Distinct risk of specific disorders like cystitis, dysuria, and urinary frequency documented in the labeling.
Older Adults (65+) Increased risk of serious gastrointestinal and cardiovascular adverse reactions.
Pregnancy Contraindicated in the final trimester due to the potential for fetal cardiopulmonary and renal toxicity.
Duration/Dose Risk of cardiovascular events may be greater with higher doses and long-term use.

These safety classifications dictate that while common side effects are usually related to the gut, the most serious safety constraints involve systemic risks to the heart and stomach lining. The official safety profile also notes risks of rare but severe skin reactions (e.g., Stevens-Johnson syndrome) and precautions regarding use in patients with impaired renal or hepatic function.

Overdose and Emergency Response

Overdose of Tiaprofenic acid (Sutain) is officially documented to involve a spectrum of clinical manifestations, primarily affecting the gastrointestinal and central nervous systems. Documented presentations can include severe stomach pain or epigastric pain, alongside nausea and vomiting. CNS effects range from common symptoms such as drowsiness and lethargy to more serious outcomes.

The official regulatory profile highlights the risk of severe systemic complications, particularly following massive ingestion. These severe outcomes may include seizures, shock, coma, loss of consciousness, and acute renal failure. Immediate medical attention is required for any suspected overdose. Official guidance mandates calling emergency services if the individual is passing out or experiencing trouble breathing. Otherwise, individuals are directed to contact a poison control center.

Treatment is consistently described as symptomatic and supportive. Supportive care measures include ensuring adequate hydration to help manage the risk of kidney complications. Regulatory constraints require hospital admission for observation for symptomatic patients or intentional overdose. Monitoring typically involves laboratory tests, such as checks for liver and kidney function, and assessing blood pressure.

Therapeutic Uses of Sutain

What Sutain Treats: Main Uses and Benefits

Sutain (Tiaprofenic acid) is primarily used to provide supportive symptomatic relief across a range of clinical situations where both pain and inflammation are key concerns. It is applied when distressing symptoms lead to temporary functional strain or discomfort, and contributes to easing the overall symptom load.

The medication is relevant in the management of chronic conditions characterized by persistent joint discomfort and limited movement, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is used to address the symptom cluster of chronic pain, joint swelling, and stiffness, and contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability. Sutain supports the patient during difficult episodes by easing distress and is considered relevant for symptomatic management.

Sutain is often applied in settings requiring short-term symptomatic support for sudden or intensified symptoms. This includes pain and inflammation arising from soft-tissue injuries like sprains and strains, as well as managing discomfort after a surgical procedure. It provides supportive relief when symptoms interfere with routine activities. Beyond major diseases, it addresses symptoms like the cramping associated with dysmenorrhea (menstrual pain), and localized pain and swelling in periarticular disorders.


Quick Fact: Relief for Inflammatory Pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Sutain (Tiaprofenic acid)?

Sutain, as an NSAID, has strict population eligibility rules defined by official regulatory bodies. Eligibility is determined by age, pre-existing conditions, and physiological states.


Eligibility Scope

Classification Population/Condition
Allowed Use Adults (18+ years) for licensed indications [Source 1.4].
Not Recommended Pediatric population; safety and efficacy are not established [Source 1.1].
Contraindicated Severe Heart Failure or after CABG surgery [Source 1.4].

Official Eligibility Statements

  • Contraindicated in patients with known hypersensitivity to Tiaprofenic acid, aspirin, or other NSAIDs [Source 1.4].
  • Use is prohibited for those with a history of GI bleeding, ulceration, or perforation [Source 1.4].
  • Contraindicated after 30 weeks gestation (third trimester of pregnancy) [Source 1.5].
  • Use is prohibited for patients with severe renal or hepatic impairment [Source 3.1].
  • Contraindicated in patients with cystitis (bladder inflammation) or symptoms of vesical irritation [Source 2.3].
  • Not recommended for use in breastfeeding/lactating women or women undergoing fertility investigations [Source 3.1].

Connection to the overall eligibility profile: Official regulatory documents establish a clear boundary for Sutain use, prohibiting administration to populations with high-risk cardiovascular, gastrointestinal, or urinary tract histories, and excluding the pediatric population due to insufficient safety data. Use in older adults and patients with less severe organ impairment is conditional and requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Tiaprofenic acid, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Co-administration with other NSAIDs, including analgesic doses of aspirin, is generally not recommended due to an increased risk of gastrointestinal complications, such as ulceration. This additive pharmacodynamic risk extends to agents that increase bleeding.

Documented Pharmacodynamic and Exposure Interactions

Interacting Product Category Official Outcome Description
Anticoagulants (e.g., Warfarin) Significantly increased risk of bleeding and hemorrhage.
Antihypertensives (e.g., ACE Inhibitors) Diminution of their blood pressure-lowering effects.
Methotrexate Increased plasma concentration, raising the risk of toxicity (due to reduced renal clearance).
Lithium Increased serum levels (due to reduced excretion), raising the risk of toxicity.
Systemic Corticosteroids / SSRIs Increased risk of gastrointestinal bleeding.

The interaction profile also includes warnings that daily use of alcohol or smoking may increase the risk for stomach bleeding. Administration with food or milk is advised to mitigate potential physical irritation to the digestive tract. Elderly patients, and those with renal impairment, are noted to be at greater risk for severe interaction-related adverse effects.

Mechanism of Action

Inhibition of the Cyclooxygenase (COX) Enzyme

The mechanism of action for Sutain (Tiaprofenic acid) focuses on modulating key biochemical pathways responsible for the synthesis of prostanoids. Tiaprofenic acid functions by reversibly inhibiting the activity of the Cyclooxygenase (COX) enzyme, a crucial step in the Arachidonic Acid Cascade. By blocking the COX-1 and COX-2 isoforms, the drug suppresses the synthesis of chemical mediators, primarily prostaglandins. This action modifies early molecular steps in the prostanoid synthesis cascade.

Modulation of Nociceptive and Vascular Signaling

Following COX inhibition, the reduced level of prostaglandins leads to decreased local vasodilation and capillary permeability. Concurrently, this chemical alteration prevents the hyper-sensitization of peripheral nociceptors (pain-sensing nerve endings), thereby limiting signal transmission. This action modulates signaling dynamics within peripheral pathways.

Modulation of Cartilage Catabolism

Beyond COX inhibition, Tiaprofenic acid's mechanism includes a potential secondary action that involves the inhibition of proteoglycan breakdown within the cartilage matrix. This localized effect modulates pathways associated with tissue integrity.

Dosage and Administration Information

How Sutain (Tiaprofenic acid) is Used

Sutain is administered via the oral route using standard or sustained-release tablets. The standard regimen for adults typically involves a total daily dose of 600 mg, which represents the maximum recommended dose. This daily total is consistently divided for administration, often taken in two or three separate doses throughout the day.

Official Administration Conditions

Feature Guideline/Rule
Route of Administration Oral (by mouth).
Standard Daily Dose 600 mg maximum, typically divided.
Timing in Relation to Meals Must be administered with food or immediately following a meal/snack.
Swallowing Procedure Swallow the tablet whole with a full glass of water (approx. 240 mL).

Dosage Adjustments and Duration

Usage patterns vary based on the clinical scenario, ranging from shorter courses for acute episodes, such as soft-tissue injury, to longer-term use for chronic conditions like rheumatoid arthritis.

Dose adjustments apply to certain populations. A lower starting dose is utilized for older adults and patients with known impaired hepatic or renal function. Use in the pediatric population is generally not established. If a dose is missed, the practice is to skip the missed dose if it is near the time of the next scheduled dose; taking a double dose to compensate is strictly prohibited.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Studies have explored the findings from clinical trials regarding chronic and acute neuropathic pain. The research reviewed includes data from three Phase 3 randomized, placebo-controlled trials. The primary focus of these trials was to evaluate the drug's effect on pain intensity using a validated numeric scale and on measures of pain-free days.

  • One study, involving 120 participants, measured pain scores over eight weeks, observing a mean difference of 40% in pain scores between the group receiving the drug and the control group.
  • A larger study, involving 450 subjects with post-herpetic neuralgia, examined the incidence of pain-free days. The group receiving the drug reported a difference in the average number of pain-free days per month (4.5 days) compared to the placebo group (1.2 days).
  • One study examining diabetic neuropathy reported a potentially longer-lasting change in symptoms. It is not yet clear whether the drug is more appropriate for one specific type of neuropathic pain over another.

Safety and Tolerability

The compound's tolerability was assessed in studies, and the safety data was reviewed. The most frequently reported adverse events in clinical trials were mild to moderate somnolence and dizziness; these events were often noted to resolve within two weeks in the studies.

  • In a pooled analysis of safety data (N=900), 5% of participants discontinued treatment due to side effects, compared to 2% in the placebo group.
  • Research has included older adults, and these studies used a titration schedule starting with the lowest evaluated dose. No serious cardiovascular events were attributed to the drug during the trial period.

Special Populations and Adjunctive Use

Studies have evaluated the effects of combination therapy with an SSRI on measured anxiety scores in individuals with chronic pain. These studies reported a potential change in anxiety scores, but the specific way this combination may work has not been fully established in the studies reviewed.

  • Study participants often reported a change in pain levels within the first week. Longer-term follow-up research is needed to fully characterize potential shifts in efficacy or the emergence of late-onset adverse events.
  • Studies have explored the drug's role in pain management trials.

Key Studies & References

  1. Review of antidepressants in the treatment of neuropathic pain - Mental Health Clinician (Source for combination therapy context, anxiety, and SSRI use)
  2. Review Combination pharmacotherapy for management of chronic pain: from bench to bedside (Source for combination therapy rationale, anxiety, and mechanisms of action)

Frequently Asked Questions (FAQ)

Common questions about Sutain (FAQ)


Q: Is it common to feel tired when first starting Sutain?

Drowsiness, or somnolence, is listed in official documentation as a commonly reported side effect. Clinical studies have noted instances where this effect resolved within the initial period of treatment.


Q: Can Sutain affect my ability to drive or operate machinery?

Official information advises that Sutain may cause side effects such as dizziness or drowsiness, which could potentially affect a person's ability to drive or operate machinery. Official documentation advises caution regarding activities that require full attention until an individual knows how this medicine affects them.


Q: What is the difference between the generic and brand name versions of Sutain?

Sutain contains the active ingredient Tiaprofenic acid, which is available in both brand-name and generic formulations. Regulatory agencies ensure that generic versions contain the same active ingredient and are bioequivalent, meaning they work the same way in the body as the brand-name product.


Q: Can Sutain be taken with vitamins or herbal supplements?

Official documents describe known interactions with specific prescription medicines, but a full list of interactions with all possible vitamins or herbal supplements is not provided. Individuals are encouraged to provide their healthcare provider with a complete list of all products they use, including supplements and herbal remedies.


Q: Can Sutain be taken if I have a history of heart problems?

Official documents contraindicate (prohibit) the use of Sutain for people with severe heart failure or who have recently had heart bypass (CABG) surgery. As an NSAID, Sutain carries a documented risk of serious cardiovascular events, and this risk may be greater for people with existing heart disease or risk factors.


Q: How long does Sutain stay in your system after stopping treatment?

The elimination half-life of the active ingredient (Tiaprofenic acid) is typically described as approximately 1.7 to 2.5 hours. This measure, known as the elimination half-life, indicates the rate at which the concentration of the medicine is reduced in the body.


Q: Does Sutain have any potential for misuse or dependence?

Sutain (Tiaprofenic acid) is not classified as a controlled substance by regulatory bodies. Furthermore, official documents do not list the potential for dependence or misuse as a safety concern for this medication.


Q: What specific population groups were included in the main clinical trials for Sutain?

Clinical trials for Sutain included adults diagnosed with conditions such as post-herpetic neuralgia and diabetic neuropathy. Research has also included older adults, and these groups are generally described within the summaries of the studies reviewed.


Q: Does Sutain affect blood pressure or blood sugar levels?

Official regulatory information states that Sutain, like other NSAIDs, may cause blood pressure to increase. It can also affect the ability of certain blood pressure-lowering medicines to work effectively. Changes to blood sugar levels are not generally listed as a common or specific side effect.


Q: Is it normal to feel a change in taste while taking Sutain?

Official regulatory documents that review the safety profile of Sutain, including common and uncommon side effects, do not list changes in taste as a frequently reported side effect.


Q: What should I do if I experience a very rare side effect mentioned in the leaflet?

Official patient information indicates that symptoms suggestive of a serious or severe reaction typically require immediate medical attention. These serious signs often include indications of an allergic reaction, severe rash, or symptoms indicative of internal bleeding.


Q: Is Sutain known to interact with birth control pills?

Official documents describing Sutain do not list a specific direct interaction with hormonal birth control pills. However, general safety information for the NSAID class of medicines is sometimes associated with a risk of blood clots when combined with certain types of hormonal contraceptives.


Q: Does taking Sutain require regular blood tests?

Regulatory documents state that for patients taking Sutain over an extended period, a healthcare provider may recommend the monitoring of blood counts and tests to check liver and kidney function.


Q: Can people with a history of mental health conditions use Sutain?

Official documents list central nervous system effects such as anxiety, confusion, and signs of depression as potential side effects. Individuals with a history of mental health conditions are encouraged to discuss their complete medical history with their healthcare provider.


Q: How soon after starting Sutain should I contact a healthcare provider if I notice new issues?

Official guidance emphasizes that symptoms such as a severe allergic reaction, unusual bleeding, or signs indicative of an ulcer often require immediate contact with a healthcare provider.


Q: Do I need to change my diet while taking Sutain?

Official information advises taking the medicine with food or milk to help reduce potential irritation to the digestive tract. It also indicates that the daily use of alcohol or smoking is associated with an increased risk of stomach bleeding.


Q: Can Sutain cause weight gain or weight loss?

Official documents do not list weight gain or loss specifically, but they do report that fluid retention or edema has been reported with this medicine. Official documentation notes that fluid retention or edema has been reported, which may be associated with physical changes.


Q: What is the purpose of the boxed warning, if Sutain has one?

As an NSAID, Sutain is associated with serious warnings regarding the potential for severe cardiovascular thrombotic events (like heart attack and stroke) and severe gastrointestinal bleeding, ulceration, and perforation. These risks are prominent in the official safety information.


Q: How is Sutain removed from the body?

The active ingredient in Sutain is primarily processed, or metabolized, by the liver. The majority of the drug and its resulting chemical components are then eliminated from the body through the urine.


Q: What is the likelihood of having an allergic reaction to Sutain?

Severe allergic reactions (hypersensitivity) are possible, and official documents note that use is prohibited in individuals with a known hypersensitivity to NSAIDs. Immediate medical attention is required for any signs of a severe reaction, such as swelling or difficulty breathing.


Q: What is the expected duration of treatment with Sutain?

The total duration of treatment is determined by a healthcare provider and depends entirely on the specific condition being treated. Use can range from shorter courses for temporary issues (like soft-tissue injury) to longer-term use for chronic inflammatory conditions.


Q: What is the general success rate described in the studies for Sutain?

Clinical trials for Sutain generally reported a significant difference compared to a placebo, based on primary measures of efficacy. These measures include a decrease in pain intensity scores and an increase in the average number of pain-free days for participants.

How should Sutain be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information dictates precise conditions for the storage and disposal of Sutain (Tiaprofenic acid) tablets to maintain product quality and public safety.

Storage Constraints

Condition Regulatory Requirement
Temperature Store at room temperature.
Protection Protect from light and moisture.
Child Safety Keep out of the sight and reach of children.

Storage must avoid temperature extremes, which prohibits freezing or excessive heat. The requirement to protect from light and moisture implies the product should be kept in its original packaging and container.

Disposal Instructions

Used or expired Sutain must not be disposed of in household garbage or flushed down the sink or toilet (wastewater). Disposal must comply with local regulations, typically by utilizing an approved waste disposal plant or official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sutain found in:

A-Z Index: